KR100613550B1 - 이바브라딘을 포함하는 구강내분산성 약제 조성물 - Google Patents

이바브라딘을 포함하는 구강내분산성 약제 조성물 Download PDF

Info

Publication number
KR100613550B1
KR100613550B1 KR1020047011350A KR20047011350A KR100613550B1 KR 100613550 B1 KR100613550 B1 KR 100613550B1 KR 1020047011350 A KR1020047011350 A KR 1020047011350A KR 20047011350 A KR20047011350 A KR 20047011350A KR 100613550 B1 KR100613550 B1 KR 100613550B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
ibabradine
tablet
pharmaceutically acceptable
Prior art date
Application number
KR1020047011350A
Other languages
English (en)
Korean (ko)
Other versions
KR20040075366A (ko
Inventor
패트릭 우드리히
헤르베 롤랜드
마르 줄리안
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20040075366A publication Critical patent/KR20040075366A/ko
Application granted granted Critical
Publication of KR100613550B1 publication Critical patent/KR100613550B1/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1020047011350A 2002-01-23 2003-01-22 이바브라딘을 포함하는 구강내분산성 약제 조성물 KR100613550B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0200791A FR2834896B1 (fr) 2002-01-23 2002-01-23 Composition pharmaceutique orodispersible d'ivabradine
FR0200791 2002-01-23
PCT/FR2003/000198 WO2003061662A1 (fr) 2002-01-23 2003-01-22 Composition pharmaceutique orodispersible d'ivabradine

Publications (2)

Publication Number Publication Date
KR20040075366A KR20040075366A (ko) 2004-08-27
KR100613550B1 true KR100613550B1 (ko) 2006-08-16

Family

ID=27589555

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047011350A KR100613550B1 (ko) 2002-01-23 2003-01-22 이바브라딘을 포함하는 구강내분산성 약제 조성물

Country Status (28)

Country Link
US (2) US20050106238A1 (sl)
EP (1) EP1474152B1 (sl)
JP (1) JP4500052B2 (sl)
KR (1) KR100613550B1 (sl)
CN (1) CN1278688C (sl)
AR (1) AR038206A1 (sl)
AT (1) ATE348619T1 (sl)
AU (1) AU2003215706B2 (sl)
BR (1) BRPI0307056B1 (sl)
CA (1) CA2473203C (sl)
CY (1) CY1108854T1 (sl)
DE (1) DE60310526T2 (sl)
DK (1) DK1474152T3 (sl)
EA (1) EA007681B1 (sl)
ES (1) ES2278165T3 (sl)
FR (1) FR2834896B1 (sl)
GE (1) GEP20063820B (sl)
HK (1) HK1076741A1 (sl)
MA (1) MA27102A1 (sl)
MX (1) MXPA04007199A (sl)
NO (1) NO333698B1 (sl)
NZ (1) NZ533842A (sl)
PL (1) PL204938B1 (sl)
PT (1) PT1474152E (sl)
SI (1) SI1474152T1 (sl)
UA (1) UA78278C2 (sl)
WO (1) WO2003061662A1 (sl)
ZA (1) ZA200405129B (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
WO2007023775A1 (ja) * 2005-08-23 2007-03-01 Astellas Pharma Inc. 心房細動治療剤
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
US20130084335A1 (en) 2010-06-14 2013-04-04 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
CN103393611B (zh) * 2013-08-06 2015-08-19 南京正大天晴制药有限公司 一种盐酸伊伐布雷定片剂及其制备方法
WO2016102423A1 (en) * 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
GR1008821B (el) 2015-06-11 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου
CN106265582A (zh) * 2016-08-31 2017-01-04 辰欣药业股份有限公司 一种盐酸伊伐布雷定片及其制备工艺
WO2021001601A1 (en) * 2019-07-01 2021-01-07 Orion Corporation Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376147B (de) * 1980-12-15 1984-10-10 Gergely Gerhard Verfahren und vorrichtung zum granulieren eines pulvergemisches
DE3505433A1 (de) * 1985-02-16 1986-08-21 Basf Ag, 6700 Ludwigshafen Direkttablettierhilfsmittel
DE3506276C1 (de) * 1985-02-22 1986-04-24 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Direkttablettiermittel
JP3253127B2 (ja) * 1991-06-07 2002-02-04 帝國製薬株式会社 生理活性ポリペプチド含有製剤
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2710265B1 (fr) * 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
CA2179382C (en) * 1994-01-31 2009-11-10 Takao Mizumoto Intrabuccally dissolving compressed moldings and production process thereof
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JP2001526662A (ja) * 1997-05-09 2001-12-18 フェロンパテント リミテッド 舌下投与式タブレットの製造のための水溶液におけるインターフェロンの安定化
AU741992B2 (en) * 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
JP2983973B1 (ja) * 1998-10-13 1999-11-29 大正薬品工業株式会社 口腔内速崩壊性固形製剤
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
DE60036205T2 (de) * 2000-07-27 2008-05-21 Roquette Frères Granulat bestehend aus Stärke und Laktose
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible

Also Published As

Publication number Publication date
ATE348619T1 (de) 2007-01-15
CN1278688C (zh) 2006-10-11
BRPI0307056B1 (pt) 2015-06-30
CA2473203A1 (fr) 2003-07-31
WO2003061662A1 (fr) 2003-07-31
MXPA04007199A (es) 2004-10-29
CY1108854T1 (el) 2014-07-02
FR2834896A1 (fr) 2003-07-25
SI1474152T1 (sl) 2007-04-30
ES2278165T3 (es) 2007-08-01
HK1076741A1 (en) 2006-01-27
JP4500052B2 (ja) 2010-07-14
UA78278C2 (en) 2007-03-15
PL370161A1 (en) 2005-05-16
EP1474152A1 (fr) 2004-11-10
EA200400927A1 (ru) 2004-12-30
AR038206A1 (es) 2005-01-05
GEP20063820B (en) 2006-05-10
CN1622809A (zh) 2005-06-01
DE60310526D1 (de) 2007-02-01
AU2003215706B2 (en) 2007-08-02
NO333698B1 (no) 2013-08-26
NO20043440L (no) 2004-08-18
DK1474152T3 (da) 2007-04-10
AU2003215706B8 (en) 2003-09-02
FR2834896B1 (fr) 2004-02-27
ZA200405129B (en) 2005-08-31
US20100267693A1 (en) 2010-10-21
KR20040075366A (ko) 2004-08-27
DE60310526T2 (de) 2007-10-25
US20050106238A1 (en) 2005-05-19
EA007681B1 (ru) 2006-12-29
JP2005523893A (ja) 2005-08-11
PT1474152E (pt) 2007-02-28
PL204938B1 (pl) 2010-02-26
MA27102A1 (fr) 2004-12-20
EP1474152B1 (fr) 2006-12-20
NZ533842A (en) 2005-08-26
BR0307056A (pt) 2004-10-26
CA2473203C (fr) 2010-08-17

Similar Documents

Publication Publication Date Title
KR100605798B1 (ko) 아고멜라틴을 포함하는 구강내분산성 약제 조성물
JP4435424B2 (ja) 口腔内で速やかに崩壊する錠剤
US20100267693A1 (en) Orodispersible pharmaceutical composition of ivabradine
ZA200408596B (en) Demsmopressin in an orodispersible dosage form
US20100267799A1 (en) Orodispersible pharmaceutical composition of perindopril
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
KR100762598B1 (ko) 항혈전성 화합물을 포함하는 구강분산성 약제 조성물
AU2003214326B2 (en) Orally dispersible pharmaceutical piribedil composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130610

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20140529

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20150617

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20170614

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee